Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuldase
- Development stage
- Unknown
- Lead developer
- Azine Healthcare
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
**Fuldase** is an oral fixed-dose analgesic and anti-inflammatory combination marketed by Azine Healthcare. It combines serratiopeptidase, a proteolytic enzyme used for anti-inflammatory effects, with paracetamol for analgesic and antipyretic activity and diclofenac potassium, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis. The product is intended for management of pain and inflammation.
- Brand names
- Fuldase
- Other names
- diclofenac potassium + paracetamol + serratiopeptidase
02
Targets
Hb (Hemoglobin)PTGES3PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Fuldase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fuldase.